← Leaderboards
Bruce E Blough
Research Triangle Institute
$9,425,198
Attributed
$13,975,965
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,975,965 · 4
By mechanism
R01$12,239,648 · 3
R42$1,736,317 · 1
Top collaborators
- Kristy M Ainslie6 shared
- Michael Mullan3 shared
- Daniel Paris3 shared
- Brian D. Kangas1 shared
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogDesignPharmaceutical PreparationsIn VivoLeadBaseToxic EffectTherapeutic TargetGrantStructureIn VitroInhibitor/AntagonistCocaineNorepinephrinePre-ClinicalSerotoninPharmaceutical ChemistrySerotonin TransporterExcretory FunctionAlzheimer&AposDrug DevelopmentMetabolismAbsorptionSafety
Grant awards (23)
MDMA Mechanisms of Prohedonic Efficacy: A Reverse Translational Approach$766,842
R01 · FY2025 · MH
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$699,018
R42 · FY2021 · AG
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,043,412
R01 · FY2020 · AI
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$812,379
R42 · FY2020 · AG
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,092,009
R01 · FY2019 · AI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,159,484
R01 · FY2018 · AI
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$224,920
R42 · FY2018 · AG
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,279,158
R01 · FY2017 · AI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,406,823
R01 · FY2016 · AI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$38,717
R01 · FY2016 · AI
Development of Potential Treatment Medications for Drug Abuse$479,232
R01 · FY2013 · DA · contact PI
Development of Potential Treatment Medications for Drug Abuse$448,505
R01 · FY2012 · DA · contact PI
Development of Potential Treatment Medications for Drug Abuse$448,711
R01 · FY2011 · DA · contact PI
Development of Potential Treatment Medications for Drug Abuse$474,469
R01 · FY2010 · DA · contact PI
Development of Potential Treatment Medications for Drug Abuse$603,558
R01 · FY2009 · DA · contact PI
Development of Potential Treatment Medications for Drug Abuse$477,636
R01 · FY2009 · DA · contact PI
Potential Treatment Medications for Drug Abuse$415,687
R01 · FY2007 · DA · contact PI
Potential Treatment Medications for Drug Abuse$423,798
R01 · FY2006 · DA · contact PI
Potential Treatment Medications for Drug Abuse$429,742
R01 · FY2005 · DA
Potential Treatment Medications for Drug Abuse$413,196
R01 · FY2004 · DA
Potential Treatment Medications for Drug Abuse$421,441
R01 · FY2003 · DA
POTENTIAL TREATMENT MEDICATIONS FOR DRUG ABUSE$211,707
R01 · FY2001 · DA
POTENTIAL TREATMENT MEDICATIONS FOR DRUG ABUSE$205,521
R01 · FY2000 · DA